Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study

Danbee Kang1,2,9, Sang Eun Yoon3,9, Dongwook Shin4,1,4, Jin Lee1,2, Yun Soo Hong5, Se Kyung Lee6, Jeong Eon Lee6, Yeon Hee Park3, Jin Seok Ahn3, Eliseo Guallar2,5, Won Seog Kim3,7, Jungho Lee8, Seok Jin Kim3,7 and Juhee Cho1,2,5

© The Author(s) 2021

INTRODUCTION
Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy worldwide [1, 2]. The overall 5-year survival rate for people with NHL is 73%. For stage I NHL, the 5-year survival rate is more than 83%. For stage II the 5-year survival rate is close to 76% and for stage III it is more than 70%. For stage IV NHL, the 5-year survival rate is around 63%. These survival rates vary depending on the cancer’s stage and subtype [3]. Accordingly, there has been increasing interest in identifying the related risk factors to better understand NHL pathogenesis. However, there is no established etiology for NHL as this disease does not constitute a single disorder but rather a group of disorders involving heterogeneous subtypes with variable clinical behaviors and treatment outcomes. Currently, exact causal relationships have only been reported for some subtypes. For example, long-term immune suppressive agents can induce NHL in patients receiving immunosuppressive agents after organ transplantation and those with human immunodeficiency virus infection [4, 5]. However, as these cases account for an extremely small proportion of NHL patients, the identification of people at risk of NHL remains a challenge.

An intriguing discovery in hemato-oncology is the lower incidence of lymphomas in women than that in men [6]. Diverse incidence patterns have been observed for distinct histologic subtypes of NHL. The male predominance has been reported in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mature T/NK-cell lymphomas, anaplastic large cell lymphoma (ALCL), and unspecified types of NHL, was the outcome. During follow-up, 1564 incident cases of NHL occurred. The fully adjusted Hazard Ratio (HR) for NHL associated with the development of breast cancer was 1.64 (95% CI 1.34–2.00) after adjusting for body mass index, alcohol intake, physical activity, smoking, income, and comorbidity. The adjusted HR for NHL was much higher in younger participants who were aged <50 years and who received hormone therapy (either tamoxifen or aromatase inhibitors) than in those ≥50 years or who did not receive hormone therapy, respectively. The development of breast cancer was associated with a significantly increased risk of NHL, particularly follicular lymphoma and mature T/NK-cell lymphoma. In particular, the risk of NHL was higher in patients receiving hormone therapy and in younger patients.

Blood Cancer Journal (2021) 11:200; https://doi.org/10.1038/s41408-021-00595-0
results were based on small numbers of NHL cases [10, 11]. Japanese patients with breast cancer have a 3.5-fold higher risk of NHL compared to the general population [12]. In the Netherlands, patients with early breast cancer had a 1.19-fold increased risk of NHL (95% confidence interval [CI] 0.61–2.08) compared to the general population [11]. A Korean multicenter study reported a standardized incidence ratio of NHL of 1.86 (95% CI 0.21–6.72) among 3444 patients with breast cancer, using the general population for comparison. However, previous studies had limitations because they provided little information about the type of cancer treatment, especially anti-hormone therapy, menopause, and lifestyle variables that could affect the occurrence of a second malignancy. Thus, we conducted a nationwide cohort study to evaluate the incidence of NHL in breast cancer survivors.

MATERIALS AND METHODS

Study population and design

We conducted a retrospective cohort study using a population-based national registry. Korea has a universal single-payer national health insurance system; the National Health Insurance Service (NHIS) maintains the national records of all covered inpatient and outpatient visits, procedures, and prescriptions. The NHIS also includes information on risk factor levels for common chronic conditions collected during routine health screening examinations supported by the national health system. Among all Korean women aged ≥20 years between 2002 and 2016 without a history of cancer (defined as an International Classification of Diseases 10th Revision [ICD-10] C code in any prior claim) as of 2002, we selected those with incident breast cancer (ICD-10 code C50) between January 1, 2003, and December 31, 2016 (Fig. 1). Because our study aimed to evaluate the long-term effects of breast cancer on the incidence of NHL, we restricted our analysis to patients who received curative treatment for breast cancer (procedure codes for breast surgery, N7131 to N7135; N = 158,804). We then identified a 1:10 age- and region-matched sample of women who did not develop breast cancer during the study period (non-breast cancer controls; N = 1,584,338). From among breast cancer cases and non-breast cancer controls, we selected participants who underwent at least one health screening exam during the study period (98,189 breast cancer cases and 1,247,777 non-breast cancer controls) and excluded 203,323 participants who presented with any cancer (ICD-10 code C) before the health screening examination, as the health screening examination constituted the baseline for the current study. The final sample size was 1,142,643 (84,969 breast cancer cases and 1,057,674 non-breast cancer controls). The Institutional Review Board of Samsung Medical Center approved this study (IRB number: 2017-08-147) and waived the requirement for informed consent, as we used only de-identified data.

Data collection

The NHIS data comprises data from four databases: those on insurance eligibility, medical treatments, medical care institutions, and general health examinations. In addition, we used national cancer screening data. The insurance eligibility database contains information on patient age, sex, residential area, type of health insurance, income level, and disability. The medical treatment database contains information on treatment bills, including details of diseases and prescriptions. NHIS claims for inpatient and outpatient visits, procedures, and prescriptions were coded using the ICD-10, which was adopted in Korea in 1995, and the Korean Drug and Anatomical Therapeutic Chemical Codes [13, 14].

The main study exposure was the development of incident breast cancer (ICD-10 code C50). Breast cancer was confirmed based on the presence of a C50 code in more than three claims within 1 year or in an inpatient hospitalization claim in the medical treatment database. Treatments for breast cancer were identified from claims filed within 1 year of breast cancer diagnosis and used to classify patients as those treated with only surgery or surgery plus chemotherapy, radiation therapy, or hormone treatment.

The study outcome was the development of NHL (all subtypes). NHL was confirmed based on the presence of C82–C85 or C96 codes in more than three claims within 1 year or in an inpatient. We further categorized NHL into five groups: Diffuse large B-cell lymphoma (DLBCL) (ICD-10, C83.3), follicular lymphoma (ICD-10, C82), mature T/NK-cell lymphomas (ICD-10, C84), ALCL (ICD-10, C84.6, C84.7), and others (C96). The NHIS routinely audits the claims; these data are considered reliable and have been used in numerous peer-reviewed publications [1, 15]. According to a recent study, definitions of cancer diagnosis in our study is an accurate and valid method to identify cancer incidence using health insurance claim data [16].

Patient age and income levels were determined from the insurance eligibility database. Data on smoking habits, drinking habits, physical activity, height, and weight were obtained from the health screening examination database. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. We used data on the age at menarche and age at menopause from the national cancer screening data and generated a variable for menopausal status at the first health screening examination.

Statistical analysis

The participants were included in the study on the date of their first health screening examination (baseline) and were followed up until the development of a study endpoint, death, or the end of the study period (December 31, 2016). The study endpoint was the development of NHL.

Fig. 1 Flow chart of the study participants.
The study exposure was breast cancer development, which was considered a time-varying variable. Thus, unexposed person-time was contributed by women who never developed breast cancer, as well as by women who developed breast cancer before developing it. For each outcome, cases of breast cancer occurring after developing a study endpoint (outcome) were not included in the analysis as participant follow-up ended with the development of a study outcome. Since cancer patients receive various exams prior to cancer treatment, to reduce the potential impact of surveillance bias we considered that outcomes occurring in the first 31 days after a diagnosis of breast cancer corresponded to unexposed person-time. Cumulative incidences were estimated using the Kaplan–Meier method. We calculated hazard ratios (HRs) with 95% CIs for developing NHL using a proportional hazards regression model with age as the time scale.

To account for potential confounding factors at the health screening examination (baseline), we adjusted for BMI categories (underweight, normal, overweight, obese, and unknown), alcohol intake (none, moderate, heavy, and unknown), moderate–vigorous physical activity (none, 1–2 times per week, >3 times per week, and unknown), smoking status (never, ever, or unknown), income percentile (Medical Aid, <30th, 31st–70th, >70th percentile), and presence of comorbid conditions at the time of the health screening examination.

To estimate age-dependent effects, we conducted time-varying analyses according to the split-age interval. Participants were assigned to the <50 years age group until they reached the age of 50 years and to the age ≥ 50 years age group. Furthermore, to evaluate the temporal effects of breast cancer, follow-up duration was classified as <1, 1 to <3, 3 to <5, and ≥5 years from the time of breast cancer diagnosis.

We also performed an additional analysis in women who developed breast cancer to estimate treatment effects. Owing to the substantial overlap of treatment modalities (chemotherapy, radiation therapy, and hormone therapy), we used non-exclusive categories in the analysis of treatment modalities (for instance, the analysis of participants who received chemotherapy compared all participants who received chemotherapy to those who did not, irrespective of other treatment modalities). In addition, to account for competing risks due to mortality, we fitted a proportional subdistribution hazards regression model with death as the competing event.

To estimate age-dependent effects, we conducted time-varying analyses according to the split-age interval. Participants were assigned to the <50 years age group until they reached the age of 50 years and to the age ≥ 50 years age group. Furthermore, to evaluate the temporal effects of breast cancer, follow-up duration was classified as <1, 1 to <3, 3 to <5, and ≥5 years from the time of breast cancer diagnosis.

We also performed an additional analysis in women who developed breast cancer to estimate treatment effects. Owing to the substantial overlap of treatment modalities (chemotherapy, radiation therapy, and hormone therapy), we used non-exclusive categories in the analysis of treatment modalities (for instance, the analysis of participants who received chemotherapy compared all participants who received chemotherapy to those who did not, irrespective of other treatment modalities). In addition, to account for competing risks due to mortality, we fitted a proportional subdistribution hazards regression model with death as the competing event.

RESULTS

Compared to participants who developed breast cancer (N = 84,969; 424,669 person-years of follow-up), non-breast cancer controls (N = 1,057,674; 10,648,319 person-years of follow-up) had similar characteristics at the time of the baseline health screening examination (Table 1). During 11,072,988 person-years of follow-up, 1,564 incident cases of NHL occurred. Of these, 105 occurred after the development of breast cancer (incidence rate 2475 per 10,000,000 person-years), and 1459 occurred before the development of breast cancer or in participants who did not develop cancer (incidence rate 1370 per 10,000,000 person-years; Fig 2A and Table 2). The HR for NHL associated with the development of breast cancer was 1.64 (95% CI = 1.34–2.00). The association did not change significantly after adjusting for confounding factors (fully adjusted HR = 1.64; 95% CI = 1.34–2.00). While participants with obesity and ever smokers had a higher risk of NHL, the associations were not statistically significant (Supplement Table 1).

In addition, a proportional subdistribution hazards regression model with death as the competing event showed similar findings (not shown). The development of breast cancer was associated with a significantly increased risk of follicular lymphoma (HR = 3.56, 95% CI = 1.88, 6.72), mature T/NK-cell lymphoma (HR = 2.75, 95% CI = 1.55, 4.90), and ALCL (HR = 7.46; 95% CI = 2.70–20.59, Table 2).

The adjusted HR for NHL was much higher in participants aged <50 years (fully adjusted HR = 2.91; 95% CI = 2.03–4.16) than in older participants (fully adjusted HR = 1.36; 95% CI = 1.08–1.73) (P for interaction <.01). Age-related effects were observed for all subtypes (Table 2). The excess risk for NHL was higher in the first 2 years after breast cancer diagnosis (Table 3). The fully adjusted HRs for NHL at <1, 1 to <3, 3 to <5, and ≥5 years after breast cancer diagnosis were 2.59 (95% CI = 1.79–3.74), 1.62 (95% CI = 1.13–2.31), 1.41 (95% CI = 0.91–2.19), and 1.29 (95% CI = 0.87–1.91), respectively. Although not statistically significant, the risk of follicular lymphoma (HR = 2.12, 95% CI = 0.58, 8.66) and mature T/NK-cell lymphomas (HR = 2.11, 95% CI = 0.67, 6.66) remained two times higher risk of NHL compared to the non-breast cancer even more than 5 years after the initial diagnosis. Among the Mature T/NK-cell lymphomas, ALCL remained significantly elevated more than 5 years after the initial diagnosis (fully adjusted HR = 10.73; 95% CI = 2.42–47.56). The pattern was similar in women <50 or ≥50 years old (Supplement Table 2).

Among the patients who developed breast cancer, the most common combinations of therapies with surgery were chemotherapy and radiotherapy (N = 38,541, 45.4%); radiotherapy (N = 14,836, 17.5%); and chemotherapy, radiotherapy, and hormone therapy (N = 10,970, 12.9%) (Fig. 1). While other treatments were not associated with an increased incidence of NHL, patients who received hormone therapy had a substantially increased risk of all

### Table 1. Characteristics of the study participants at the baseline health screening examination (N = 1,142,643).

| Characteristics | No breast cancer (N = 1,057,674) | Incident breast cancer (N = 84,969) |
|-----------------|---------------------------------|----------------------------------|
| Age at baseline, years | 46 (40–54) | 46 (40–53) |
| Age at menarche, years |  |  |
| <10 | 2660 (0.3) | 394 (0.5) |
| 10–13 | 73,185 (6.9) | 7025 (8.3) |
| 14–16 | 482,512 (45.6) | 41,278 (48.6) |
| ≥17 | 398,988 (37.7) | 27,696 (32.6) |
| Unknown | 100,329 (9.5) | 8578 (10.1) |
| Menopause status |  |  |
| Pre-menopause | 404,672 (38.3) | 30,291 (35.7) |
| Post-menopause | 556,829 (52.7) | 46,501 (54.7) |
| Missing data | 96,163 (9.1) | 8177 (9.6) |
| BMI, kg/m² |  |  |
| Underweight (<18) | 38,847 (3.7) | 3035 (3.6) |
| Normal (18 to <23) | 474,009 (44.8) | 37,724 (44.0) |
| Overweight (23 to <25) | 243,220 (22.3) | 19,577 (23.0) |
| Obese (≥25) | 301,127 (28.5) | 24,604 (29.0) |
| Missing data | 471 (0.0) | 29 (0.0) |
| Alcohol consumption |  |  |
| None | 713,524 (67.5) | 58,034 (68.3) |
| Moderate (1–19 g/day) | 275,882 (26.1) | 21,469 (25.3) |
| Heavy (≥20 g/day) | 20,848 (2.0) | 1497 (1.8) |
| Missing data | 47,420 (4.5) | 3978 (4.7) |
| Smoking status |  |  |
| Never smoker | 946,369 (89.5) | 75,647 (89.0) |
| Ever smoker | 58,619 (5.5) | 4767 (5.6) |
| Missing data | 52,686 (5.0) | 4555 (5.4) |
| Moderate–vigorous physical activity |  |  |
| None | 610,131 (57.7) | 48,480 (57.1) |
| 1–2 times per week | 204,126 (19.3) | 16,719 (19.7) |
| ≥3 times per week | 195,661 (18.5) | 15,701 (18.5) |
| Missing data | 47,756 (4.5) | 4069 (4.8) |
| Income percentile |  |  |
| Medical Aid | 19,753 (1.9) | 1480 (1.7) |
| <30th | 304,541 (28.8) | 23,692 (27.9) |
| 31st–70th | 357,873 (33.8) | 28,465 (33.5) |
| >70th | 375,507 (35.5) | 31,332 (36.9) |

BMI body mass index. Values in the table are medians (interquartile range) or numbers (percentage).
subtypes of NHL compared to patients who did not receive hormone therapy (fully adjusted HR = 2.68; 95% CI = 1.83–3.94) (Table 4). Especially, risk of DLBCL (HR = 2.15; 95% CI = 0.83, 5.55) and NK/T lymphoma (HR = 3.91; 95% CI = 1.31, 11.64) were increased after breast cancer among patients with anti-hormone therapy.

The development of breast cancer was associated with a significantly increased risk of both NHL other than ALCL (fully adjusted HR = 1.57; 95% CI = 1.28–1.93, Fig. 2B and Table 2) and ALCL (fully adjusted HR = 7.46; 95% CI = 2.70–20.59, Fig. 2C and Table 2). Moreover, the risk of ALCL remained significantly elevated more than 5 years after the initial diagnosis (fully adjusted HR = 15.52; 95% CI = 4.42–54.41).

**DISCUSSION**

In this large national cohort, breast cancer increased the risk of subsequent development of NHL. The risk of NHL was much higher in patients who were younger than 50 years and patients who received anti-hormone therapy. Especially higher risk of DLBCL was associated with anti-hormone therapy. The increased risk of NHL was evident shortly after cancer development, was highest in the first 2 years after a breast cancer diagnosis, and remained elevated throughout the rest of the follow-up period.

While previous studies have observed an increased incidence of treatment-related leukemia following chemotherapy [18], its association with the incidence of NHL is controversial [12]. In our study, we observed no association between chemotherapy or
radiation therapy and NHL incidence. However, hormone therapy was significantly associated with an increased risk of NHL. According to previous literature, estrogen may have protective effects against the risk of NHL [19, 20]. In a population-based case-control study, women with NHL who had taken oral contraceptives or estrogen-containing lactation suppressants demonstrated that estrogen exposure essentially reduced the risk of NHL by half [21]. In contrast, anti-hormone therapy was associated with an increased risk of lymphoma. A tamoxifen trial demonstrated an increased risk of leukemia/lymphoma/myeloma among women randomized to the tamoxifen group (HR = 1.58, 95% CI = 0.86–2.98) [22]. However, the causal relationship between estrogen and NHL is unclear and could vary according to subtype. In this study, we found that the risk of follicular lymphoma and mature T/NK-cell lymphomas was increased after breast cancer. According to a meta-analysis of cohort data evaluating the association of

| Table 2. Hazard ratios (95% CI) for incident NHL associated with incident breast cancer. |
|---------------------------------------------------------------|
| **Incidence rate per 10,000,000 person-years** | **Adjusted HR (95% CI)** | **P-value** |
| NHL | 1370 | 2473 | 1.64 (1.34, 2.00) | <0.01 |
| Age < 50 years | 773 | 2354 | 2.91 (2.03, 4.16) | <0.01 |
| Age ≥ 50 years | 1821 | 2531 | 1.36 (1.08, 1.73) | 0.01 |
| DLBCL | 308 | 424 | 1.19 (0.74, 1.92) | 0.47 |
| Age < 50 years | 124 | 214 | 1.49 (0.47, 4.76) | 0.50 |
| Age ≥ 50 years | 447 | 527 | 1.15 (0.68, 1.93) | 0.61 |
| Follicular lymphoma | 69 | 259 | 3.56 (1.88, 6.72) | <0.01 |
| Age < 50 years | 37 | 357 | 10.22 (3.73, 27.96) | <0.01 |
| Age ≥ 50 years | 92 | 211 | 2.26 (0.98, 5.26) | 0.06 |
| Mature T/NK-cell lymphomas | 102 | 306 | 2.75 (1.55, 4.90) | <0.01 |
| Age < 50 years | 63 | 214 | 3.16 (0.96, 10.44) | 0.06 |
| Age ≥ 50 years | 132 | 351 | 2.65 (1.37, 5.11) | <0.01 |
| ALCL | 14 | 118 | 7.46 (2.70, 20.59) | <0.01 |
| Age < 50 years | 7 | 14 | 18.82 (3.11, 113.70) | <0.01 |
| Age ≥ 50 years | 20 | 105 | 5.28 (1.49,18.74) | <0.01 |
| Other NHL* | 89 | 148 | 1.54 (1.19, 1.98) | <0.01 |
| Age < 50 years | 55 | 157 | 2.78 (1.80, 4.31) | <0.01 |
| Age ≥ 50 years | 115 | 144 | 1.23 (0.90, 1.69) | 0.19 |

ALCL anaplastic large cell lymphoma, DLBCL Diffuse large B-cell lymphoma, NHL non-Hodgkin lymphoma. Age as the time scale. Adjusted for body mass index categories (underweight, normal, overweight, obese, and unknown), alcohol consumption (none, moderate, heavy, and unknown), moderate–vigorous physical activity (none, 1–2 times per week, >3 times per week, and unknown), smoking status (never, ever, or unknown), and income percentile (Medicaid, ≤30th, 31st–70th, >70th).

| Table 3. Association of incident NHL with incident breast cancer according to the time after diagnosis. |
|---------------------------------------------------------------|
| **Incidence of non-Hodgkin lymphoma** | **Non-Hodgkin lymphoma** | **DLBCL** | **Follicular lymphoma** | **Mature T/NK-cell lymphomas** | **ALCL** | **Other NHL*** |
| No breast cancer | Reference | Reference | Reference | Reference | Reference | Reference |
| <1 year after diagnosis | 2.59 (1.79, 3.74) | 2.36 (1.05, 5.29) | 7.20 (2.63, 19.70) | 3.62 (1.15, 11.40) | – | 2.20 (1.34, 3.61) |
| P-value | <0.01 | 0.04 | <0.01 | 0.03 | – | <0.01 |
| 1 to < 3 years after diagnosis | 1.62 (1.13, 2.31) | 0.68 (0.22, 2.12) | 4.34 (1.59, 11.89) | 3.52 (1.44, 8.63) | 9.71 (2.22, 42.51) | 1.53 (0.97, 2.41) |
| P-value | <0.01 | 0.51 | <0.01 | <0.01 | <0.01 | 0.07 |
| 3 to < 5 years after diagnosis | 1.41 (0.91, 2.19) | 1.19 (0.44, 3.19) | 1.48 (0.20, 10.63) | 1.90 (0.47, 7.70) | 6.87 (0.91, 52.14) | 1.43 (0.83, 2.47) |
| P-value | 0.13 | 0.73 | 0.70 | 0.37 | 0.06 | 0.20 |
| ≥5 years after diagnosis | 1.29 (0.87, 1.91) | 1.05 (0.43, 2.53) | 2.12 (0.58, 8.66) | 2.11 (0.67, 6.66) | 10.73 (2.42, 47.56) | 1.22 (0.73, 2.03) |
| P-value | 0.21 | 0.92 | 0.30 | 0.20 | <0.02 | 0.45 |

ALCL anaplastic large cell lymphoma, DLBCL Diffuse large B-cell lymphoma, NHL non-Hodgkin lymphoma, HR hazard ratio, CI confidence interval, NHL non-Hodgkin lymphoma. Age as the time scale. Adjusted for body mass index categories (underweight, normal, overweight, obese, and unknown), alcohol consumption (none, moderate, heavy, and unknown), moderate–vigorous physical activity (none, 1–2 times per week, >3 times per week, and unknown), smoking status (never, ever, or unknown), and income percentile (Medicaid, ≤30th, 31st–70th, >70th).
Table 4. Association of incident NHL with incident breast cancer according to treatment status.

| Type of treatment after breast cancer | DLBCL HR (95% CI) | Follicular lymphoma HR (95% CI) | Mature T/NK-cell lymphomas HR (95% CI) | ALCL HR (95% CI) | P-value | Other NHL* HR (95% CI) | P-value |
|-------------------------------------|-------------------|---------------------------------|--------------------------------------|-----------------|---------|----------------------|---------|
| Any treatment                        | 0.77 (0.41, 1.43) | 0.40 (0.15, 1.74)               | 0.37 (0.11, 1.26)                    | 0.40 (0.12, 1.48) | 0.24    | 0.83 (0.36, 1.92)    | 0.66    |
| Incident breast cancer without therapy | 0.76 (0.41, 1.43) | 0.40 (0.15, 1.74)               | 0.37 (0.11, 1.26)                    | 0.40 (0.12, 1.48) | 0.24    | 0.83 (0.36, 1.92)    | 0.66    |
| Incident breast cancer with chemotherapy | 0.76 (0.41, 1.43) | 0.40 (0.15, 1.74)               | 0.37 (0.11, 1.26)                    | 0.40 (0.12, 1.48) | 0.24    | 0.83 (0.36, 1.92)    | 0.66    |
| Incident breast cancer with radiation therapy | 0.76 (0.41, 1.43) | 0.40 (0.15, 1.74)               | 0.37 (0.11, 1.26)                    | 0.40 (0.12, 1.48) | 0.24    | 0.83 (0.36, 1.92)    | 0.66    |
| Incident breast cancer with anti-estrogen therapy | 2.68 (0.39, 18.06) | 0.82 (0.11, 6.10)               | 0.81 (0.12, 5.00)                    | 0.81 (0.12, 5.00) | 0.81    | 0.80 (0.37, 1.71)    | 0.81    |
| Incident breast cancer without hormone | 0.81 (0.46, 1.40) | 0.81 (0.37, 1.71)               | 0.81 (0.46, 1.40)                    | 0.81 (0.46, 1.40) | 0.81    | 0.81 (0.46, 1.40)    | 0.81    |

Hazard ratio, CI confidence interval, ALCL anaplastic large cell lymphoma, DLBCL diffuse large B-cell lymphoma, NHL non-Hodgkin lymphoma, ALCL anaplastic large cell lymphoma, DLBCL diffuse large B-cell lymphoma, NHL non-Hodgkin lymphoma, ALCL anaplastic large cell lymphoma, DLBCL diffuse large B-cell lymphoma, NHL non-Hodgkin lymphoma.

*Other NHL includes MALT lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, myeloma, plasma cell myeloma, chronic myeloid leukemia, hairy cell leukemia, immunoblastic lymphoma, lymphoblastic lymphoma, lymphomatoid granulomatosis, marginal zone lymphomas (follicular, MALT, nodal), primary central nervous system lymphoma.

In our study, the association between breast cancer and the diagnosis of NHL was significantly stronger in patients younger than 50 years than in those older than 50 years. Young age has been identified as a risk factor for the development of second primary cancers among breast cancer survivors [24, 25]. Furthermore, age < 50 years was associated with a higher risk of second primary cancers [26]. Patients who develop breast cancer at a young age might have more genetic and environmental risk factors, and aggressive treatment for breast cancer might lead to carcinogenesis [27–29]. Thus, further attention is required in young populations. Currently, surveillance is recommended in breast cancer survivors after initial treatment based on their symptoms [30]. Therefore, the development of more comprehensive care strategies is required based on research on the epidemiology, screening, and chemoprevention of second primary cancers [31]. We also found that the patients who received anti-estrogen therapy had a higher risk of NHL, particularly of DLBCL. While FL is associated with estrogenic effects, DLBCL may be more related to a lack of estrogen status. Castration accelerated lymphoma growth in C57BL6 male mice grafted with murine EG7 T cell lymphoma cells. In contrast, inhibition of androgen-to-estrogen conversion by the letrozole induced faster lymphoma growth in mice, suggesting that androgens impact lymphoma growth through their conversion to estrogens [32]. Further studies are necessary to evaluate the impact of hormones on incident NHL.

We also observed a high excess risk of NHL within 3 years of breast cancer diagnosis. These effects might be associated with hormone deprivation due to breast cancer treatment. In contrast, the risk of ALCL remained significantly elevated more than 5 years after the initial diagnosis. As reported by the US and global data as of July 2019, the median age at the time of diagnosis was 53 years (range 27–90 years), and the median time from the last breast implantation to an ALCL diagnosis was 8 years (range 0–34 years) [33]. In a report of six cases of BIA-ALCL in Germany, most cases manifested 7–10 years after implantation [34]. As the number of breast cancer survivors undergoing breast plastic surgery increases by five-fold each year [35], the cumulative incidence of BIA-ALCL is rapidly increasing; [36] thus, the National Comprehensive Cancer Network published guidelines on BIA-ALCL in 2019 [37]. According to these guidelines, when diagnosed early, BIA-ALCL is commonly indolent and slow-growing with an excellent prognosis. Therefore, appropriate surveillance should be performed to ensure timely diagnosis and treatment. Patients with symptomatic periprosthetic effusions occurring more than 1 year after implantation should be tested for BIA-ALCL [37].

Our study has several limitations. First, data on exposure and outcomes were extracted from claims data. However, the identification of cancer cases based on claims is considered reliable in Korea, as cancer codes are reviewed by the NHIS and have implications for additional patient benefits. While these data are subject to errors, claims data for the clinical outcomes evaluated in this study are highly specific and have been widely used in population studies. Second, the NHIS claims data do not contain information on laboratory, imaging, pathology, family history, or reproductive profile; we did not have information on cancer stage, type of hormone, and germline mutations in the breast tumors. Further studies with detailed clinical data are necessary to confirm the study findings. Third, there are services
and treatments that are not covered by national health insurance, including preventative surgery, over-the-counter drugs, and cosmetic surgery. Thus, we could not determine whether the participants had received breast implants. Since 2015, the national health insurance in Korea has covered breast reconstruction; thus, studies are needed after the accumulation of sufficient follow-up data to observe cancer outcomes. In addition, we were not able to adjust for the potential confounding effects of breast implants or birth control pill use. However, when we used data from the baseline health screening exam, the proportion of women who took birth control pills among those without and with breast cancer was 5.5 and 4.7%. In addition, the proportion of hormone replacement therapy at the baseline health screening exam was similar among women without (10%) and with (9.7%) breast cancer. It is thus unlikely that the use of estrogen-based contraceptives or hormone replacement therapy can explain the differences between the groups. Fifths, patients who develop breast cancer have more frequent contact with the health care system, which may induce surveillance bias. Finally, although we had sufficient statistical power to observe the incidence of NHL in breast cancer patients, a longer follow-up duration may be needed given the incidence of various subtypes of NHL. However, this study’s strength was its nationwide cohort study design that included a relatively large number of NHL cases and consideration of the types of cancer treatments and lifestyle variables that could affect the occurrence of a second malignancy. Finally, the association of breast cancer with overall NHL may depend on the breast cancer treatment or the mix of subtypes of NHL, which may be different in different populations [38]. One of the key characteristics of breast cancer in Korea is the higher incidence of young-age breast cancer than in Western countries [39]. Related to the difference in age distribution, the pattern of treatment for breast cancer is also different than in Western countries. Additionally, the type of NHL also differs with respect to western. Compared to Western countries, Korea has a higher frequency of follicular lymphoma and NK/T cell lymphomas which are relatively more strongly associated with incident breast cancer [40]. Therefore, our findings may not be generalizable to other settings with different incidence rates for different types of NHL. Regardless of the limitations, this study has several strengths. The study used a national dataset that included a relatively large number of NHL cases. We also had information on the types of cancer treatment. In addition, we used health screening examination data and could include important lifestyle variables that could affect the occurrence of a second malignancy such as smoking drinking, physical activity, and BMI.

In conclusion, breast cancer development was associated with an increased risk of NHL development. In particular, the risk of NHL was higher in patients receiving hormone therapy and in younger patients. In addition, the excess risk of NHL was higher within 3 years after breast cancer diagnosis. Surveillance guidelines should be developed to screen for NHL in patients with breast cancer, especially those diagnosed at a younger age and who received hormone therapy.

REFERENCES

1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.
2. Bowzoky Al-Naab A, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. BMJ. 2018;362:k3204.
3. National Cancer Institute. Cancer stat facts: non-Hodgkin lymphoma retrieved. National Cancer Institute; 2021.
4. Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdíc CM, Skibola CF, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014:130–44.
5. Dal Maso L, Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemophagocytic neoplasms in people with AIDS. Lancet Oncol. 2003;4:110–9.
6. Yakimchuk K, Hasni MS, Guan J, Chao MP, Sander B, Okret S, et al. Inhibition of lymphoma vascularization and dissemination by estrogen receptor β agonists. Blood. 2014;123:2054–61.
7. Parkin DM. 11. Cancers attributable to infection in 2010. Br J Cancer. 2011;105:549–56.
8. Rajamäki A, Sunela K, Prusila REI, Kuusisto MEL, Mercadal S, Selander T, et al. Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months. Leuk lymphoma. 2021;62:1639–47.
9. Roemer K, Pfreundschuh M. How do estrogens control lymphoma? Blood. 2014;123:1980–1.
10. Jung HK, Park S, Kim NW, Lee JE, Kim Z, Han S, et al. Development of second primary cancer in Korean breast cancer survivors. Ann Surg Treat Res. 2017;93:287–92.
11. Honing MJ, Alemán BM, van Rosmalen AJ, Kuenen MA, Klijn JG, van Leeuwen FE, et al. Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. Int J Radiat Oncol Biol Phys. 2006;64:1081–91.
12. Tanaka H, Tsukuma H, Koyama H, Kinoshita Y, Kinoshita N, Oshima A, et al. Second primary cancers following breast cancer in the Japanese female population. Jpn J cancer Res. Gann 2001;92:1–8.
13. ChangBae, C, SoonYoung, K, JunYoung, L & SongYi, L Republic of Korea: health system review. Health Syst Transit. 2009. https://apps.who.int/iris/handle/10665/33037.
14. Korea Pharmaceutical Information Service. Korea pharmaceutical information http://www.kpis.or.kr/. 2016.
15. Shin DW, Cho B, Guallar E. Korean National Health Insurance database. JAMA Intern Med. 2016;176:138.
16. Yang, MS, Park, M, Back, JH, Lee, GH, Shin, JH, Kim, K & et al. Validation of cancer diagnosis based on the National Health Insurance Service Database versus the National Cancer Registry database in Korea. Cancer Res Treat. 2021. https://doi.org/10.4143/crt.2021.044.
17. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
18. Kufe DW, Pollock RE, Weichselbaum RR, Robert CB, Ted SG, James FH, Holland-Frei Cancer medicine. 6th ed. Decker Periodicals Publ Incorporated; 2003.
19. Roemer K, Pfreundschuh M. How do estrogens control lymphoma? Blood. 2014;123:1980–1.
20. Kane EV, Bernstein L, Bracci PM, Cerhan JR, Costas L, Dal Maso L, et al. Post-menopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studies. Ann Oncol. 2013;24:433–41.
21. Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate-or high-grade B-Cell non-Hodgkin’s lymphoma in women. J Clin Oncol: Off J Am Soc Clin Oncol. 2001;19:1381–7.
22. Cuzick J, Sestak I, Cawthorn S, Hamed H, Holfi K, Howell A, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16:67–75.
23. Bouman A, Heineman MJ, Faas MM, Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11:411–23.
24. Rubino C, de Vathaire F, Diallo I, Shamsaldin A, Lê MG. Increased risk of second cancers following breast cancer: role of the initial treatment. Breast cancer Res Treat. 2000;61:183–95.
25. Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118:2885–92.
26. Lin CY, Chen S-H, Huang C-C, Weng S, Lee S-T, Guo H-R, et al. Risk of secondary cancers in women with breast cancer and the influence of radiotherapy: a national cohort study in Taiwan. Med (Baltim). 2016;95:e5556.
27. Yu GP, Schantz SP, Neugut AI, Zhang ZF. Incidences and trends of second cancers following breast cancer: role of the initial treatment. Breast cancer Res Treat. 2000;61:183–95.
28. Molina-Montes E, Requena M, Fernández MF, Arroyo-Morales M, Espín J, et al. Risk of second cancers following breast cancer patients: a fixed inception cohort-based analysis (United States). Cancer causes control. CCC. 2006;17:411–20.
29. Brown LM, Chén BE, Pfeiffer RM, Schairer C, Hall P, Storm H, et al. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast cancer Res Treat. 2007;106:439–51.
30. Molina-Montes E, Requena M, Sánchez-Cantalejo E, Fernández MF, Arroyo-Morales M, Espín J, et al. Risk of second cancers after a first primary breast cancer: a systematic review and meta-analysis. Gynecologic Oncol. 2015;136:158–71.
31. Wilbur J. Surveillance of the adult cancer survivor. Am Fam Physician. 2015;91:29–36.
32. Albers DS. Second cancers are killing us! Cancer Epidemiol Biomarkers Prev. 2006;15:2019.
33. Talaber G, Yakimchuk K, Guan J, Inzunza J, Okret S. Inhibition of estrogen biosynthesis enhances lymphoma growth in mice. Oncotarget. 2016;7:20718–27.
34. US Food and Drug Administration. Medical device reports of breast implant-associated anaplastic large cell lymphoma. https://www.fda.gov/medical-devices/breast-implants/medical-device-reports-breast-implant-associated-anaplastic-large-cell-lymphoma. Accessed 20 Aug 2020.
35. Kirchhoff J, Fellenberg EM, Solbach C, Gerber-Schäfer C, Rancós C, Fritsche UV, et al. Breast implant-associated lymphoma. Dtsch Arztebl Int. 2018;115:628–35.
36. Carter SA, Lyons GR, Kuerer HM, Bassett RL, Oates S, Thompson A, et al. Operative and oncologic outcomes in 9861 patients with operable breast cancer: single-
institution analysis of breast conservation with oncoplastic reconstruction. Ann Surgical Oncol. 2016;23:3190–8.

36. Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, et al. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol: Off J Eur Soc Med Oncol. 2016;27:306–14.

37. Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthetic Surg J. 2019;39:53–513.

38. Curtis, RE. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute; 2006.

39. Kang SY, Kim YS, Kim Z, Kim HY, Kim HJ, Park S, et al. Breast cancer statistics in Korea in 2017: data from a breast cancer registry. J breast cancer. 2020;23:115–28.

40. Jung H-R, Huh J, Ko Y-H, Jeon YK, Yoon SO, Kim SH, et al. Classification of malignant lymphoma subtypes in Korean patients: a report of the 4th nationwide study. J Hematopathology. 2019;12:173–81.

ACKNOWLEDGEMENTS
The Ministry of Education and the Ministry of Health and Welfare of the Republic of Korea provided funding for this study. JC was funded by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare (HI19C1211). DK was funded by the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education (2017R1D1A1B03031654).

AUTHOR CONTRIBUTIONS
DK, SEY, SJK, and JC were involved in the study design. DK, JL, YSH, and EG were involved in data acquisition and management. DK, JL, YSH, EG, and JC were involved in data analysis. SEY, DS, SKL, JEL, YHP, JSA, WSK, JL, and SJK were involved in results interpretation and manuscript writing. SJK and JC made the decision to submit for publication.

CONFLICT OF INTEREST
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41408-021-00595-0.

Correspondence and requests for materials should be addressed to Seok Jin Kim or Juhee Cho.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021